Today’s AI Top Pick: IDN

8/5/2026 · Low Float Bullish Consensus Deep Rotation screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

Today's pick · Low Float Bullish Consensus Deep RotationIDNBUY NOW7.6 / 108/5/2026

IDN (Intellicheck) is the cleanest low-float, screen-passing setup on the board right now. Fundamentals are legitimately strong for a $78M micro-cap: 90.68% gross margin, 8.48% operating margin, 9.56% net margin, ROE 11.38, zero debt, salesYoY +15.26%, analyst recom 1.67, and targetUpsidePct +93.3. Fundamental score 5.75 is the second-highest in the pool and — unlike MORN and GPI — the tape isn't fighting you. The multi-timeframe forecast tape is aligned bullishly on the horizons that matter: 4h fc_short +38.31 / fc_mid +44.21 / fc_long +57.80, and 1d fc_short +10.39 / fc_mid +40.30 / fc_long +33.30. Bullish_prob is 1.0, near_term_bullish 1.0. Critically, IDN is NOT extended — 4h pos_in_21bar_range 32.08%, 1d 64.29%, and 1wk only 7.38% with a -53.24% weekly drawdown. That is a deep-rotation micro-cap sitting near a multi-month base with short-horizon forecasts turning up — exactly the low-float bullish-consensus profile the lens is designed to catch. The weekly forecast being modestly negative (-3 to -12%) is the honest caveat, but this is a swing/short-cycle entry, not a 6-month hold. Why today vs. wait: RSI 47.78 is neutral (not overbought), 1d drawdown only -4.8% (didn't just crash), and the 4h is still holding above the recent low with strong upward forecast slope. Compared to alternatives — MORN sits at pos_in_range 100% on all three TFs with a 4h fc of -11.06% (classic chase trap post-earnings), TASK reports earnings tomorrow (event risk, and near_term_bullish is only 0.2), and GPI just took two analyst PT cuts on 8/4 (JPM $275 is below the current $285.88). IDN's only recent headline is a neutral/positive CEO interview about AI-driven fraud demand — no dilution, no legal overhang, no guidance cut. Best risk/reward setup today. The screen thesis (Float ≤ 20M · Forecast Consensus ≥ 1) is satisfied cleanly, fundamentals are actually earning money (rare in this pool of biotech burn-machines), and the forecast tape confirms without you having to buy the high. That's the trifecta.

Entry zone

$3.85 – $4.00 (current $3.97; scale in on any intraday dip to $3.85 which is near the recent 4h low)

Stop loss

$3.55 (below the 4h low; roughly -10% risk, protects against a break of the base)

First target

$4.55 (approx +15%, aligned with 4h fc_short +38% pathway and the mid-range of the 1d 21-bar band)

Longer target

$5.75 – $6.25 (approx +45-58%, aligned with 4h fc_long +57.8% and 1d fc_mid +40.3%; also within striking distance of analyst upside +93.3%)

Risks

Weekly forecast tape is mildly negative (fc_short -3.01%, fc_mid -6.23%, fc_long -12.66%) — this is a short-cycle bounce trade, not a multi-month hold
Weekly drawdown of -53.24% indicates a genuine downtrend; if the 4h base at ~$3.85 breaks, next support is meaningfully lower
Micro-cap tech with $78.57M market cap and float ≤20M — thin liquidity means slippage on both entry and exit; use limits
PE 35.76 and fwdPe 22.82 are elevated in absolute terms; a broad tech-multiple compression would hit this name harder than large caps
YTD performance -41.92%, 1-yr -23.17% — sentiment is poor; needs the forecast tape to actually deliver or shorts will press

Honorable mentions

GPIStrongest 'real business' fundamentals in the pool (PE 11.92, PEG 0.77, fwdPe 6.32, recom 1.87) and sitting at pos_in_range 0% on both 1d and 1wk with 1d fc_mid +31.75%. Downgraded to BUY_PULLBACK only because JPM cut PT to $275 (below the $285.88 current print) on 8/4 — wait for a shakeout to $270-275 for cleaner entry.

TNXPPositive FDA Type C meeting catalyst (8/3) on TNX-4800 Lyme program, TONMYA Medicare coverage expanded, 1wk fc absurdly large (outlier — discount it), but 1d dd -15% and pos_in_range 44% give room. Held back by 22.56% short float and near_term_bullish only 0.2.

Full ranking (30)

#	Symbol	Verdict	Score	Read
1	IDN	BUY NOW	7.6	Solid fundamentals (90%+ GM, no debt, profitable), 4h/1d forecasts +10-57%, near mid-range, bullish_prob 1.0 — cleanest setup today.
2	GPI	BUY PULLBACK	7.1	Best 'real business' fundamentals (PE 11.9, PEG 0.77) at 0% of 1d/1wk range but 8/4 analyst PT cut to $275 warrants patience.
3	MORN	BUY PULLBACK	6.4	Top fundamentals (score 7.25) but pos_in_range 100% on every TF and 4h fc -11% — don't chase post-earnings pop.
4	TASK	WAIT	5.9	PE 5.76 / fwdPe 4.32 attractive but at 100% of 4h/1d range with earnings tomorrow — event risk too high.
5	TNXP	BUY PULLBACK	5.7	FDA Type C win and Medicare coverage bullish, but 22.56% short float and 1d fc_short -1.95% argue for patience.
6	EVGN	BUY PULLBACK	5.5	Real 4h/1d momentum (+46-55% recent_21bar) and PCSK9 partnership catalyst but at 95%+ of 4h/1d range.
7	COSM	WAIT	5.2	targetUpside 1945% and positive Albania/pharma news but 1wk fc -100% is a system-flagged blow-up signal.
8	BCDA	BUY PULLBACK	5.1	1wk fc +109-158% and 1d dd only -6% but salesYoY -100% and ROE -950 is fundamentally broken.
9	LBRDA	BUY PULLBACK	5.0	Multi-TF bullish (fc +6 to +120%) but pos_in_range 100% on 4h/1d — wait for pullback.
10	NXTC	WAIT	4.9	Avere merger + $320M PIPE changes the story entirely; 206% 21-bar move already priced the news.
11	QNTM	WAIT	4.8	4h fc +75-123% but 1wk fc_short -29% and debt settlement/dilution overhang.
12	LTRN	WAIT	4.6	Open-Medicine AI spin-out is intriguing but 4h fc_mid -0.59 / fc_long +2.2 and 1wk fc_short -4.23 — tape not confirming.
13	DRMA	WAIT	4.5	1d fc_long +230% eye-catching but $4.4M market cap and 1wk +13,938% forecast is pure outlier noise.
14	GRCE	AVOID	4.3	$10M PIPE priced today (8/5) — fresh dilution kills the near-term setup despite FDA no-deficiency finding.
15	GLMD	WAIT	4.3	Aramchol Parkinson's/cardiac progress positive but only 2 TFs available and 4h fc_short +44 vs 1d +1 — mixed.
16	INDP	BUY PULLBACK	4.2	Massive 1wk fc +520-759% and pos_in_range 5% but recent 4h dd -55% signals capitulation — needs base to form.
17	XTLB	WAIT	4.1	1wk fc +73-110% but 4h fc_short -1.64 and near_term_bullish 0 — no near-term catalyst.
18	DARE	WAIT	4.0	Debt/Eq 9.84 is extreme and 1wk fc_short -16.4 despite deep 4h dd -37%.
19	WW	WAIT	3.9	Only 1d TF available, pos_in_range 100%, earnings pending — insufficient signal.
20	HCWB	AVOID	3.8	$1.6M placement priced 7/29 at $2.58 is fresh dilution; profitMargin -274%.
21	RGNT	WAIT	3.8	Japan/EU patent wins positive but only 1d TF, 1d fc_short -13.86%, bullish_prob null.
22	ANNA	BUY PULLBACK	3.7	17.97 ROE and 30% operMargin real but pos_in_range 0-14% and no analyst upside data.
23	USBC	AVOID	3.5	pos_in_range 100% on 4h/1d with 1wk fc +1016-1299% — screaming outlier, avoid the top.
24	NXL	AVOID	3.4	Operating margin -3084% and profit margin -3022% — business economics broken.
25	PRSO	WAIT	3.4	4h/1d fc +30-55% but salesYoY -40.57% and no positive catalyst in news.
26	LUCY	AVOID	3.3	Claude AI integration positive but $3M warrant exercise dilution 7/8 and profitMargin -272%.
27	YCBD	AVOID	3.2	1d fc_short -8.11%, recent_21bar -25.87%, tape actively deteriorating.
28	IPWR	AVOID	3.0	$75M shelf filed 7/10 — massive dilution overhang on a $67M market cap; ps 2238.
29	INTZ	AVOID	2.9	1wk fc -54.91% flat across all horizons — tape signals structural break.
30	CNCK	AVOID	2.8	56.4M share resale prospectus filed 7/31 — enormous supply overhang; fwdPe 1622.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord